Pasithea Therapeutics Corp. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Tiago Reis Marques and CFO Daniel Schneiderman certified the Q2 2026 10-Q (period ended June 30, 2026) filed August 14, 2026, pursuant to SOX §302 and §906. Both officers attest that financial statements fairly present the company's condition, no material misstatements exist, and internal controls are designed and effective. No operational changes, transactions, or financial results are disclosed in these certification exhibits.
Why this rating
Routine SOX certification exhibits; no substantive business development. Standard periodic disclosure required by law.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.